ATE435281T1 - Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung - Google Patents

Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung

Info

Publication number
ATE435281T1
ATE435281T1 AT97936721T AT97936721T ATE435281T1 AT E435281 T1 ATE435281 T1 AT E435281T1 AT 97936721 T AT97936721 T AT 97936721T AT 97936721 T AT97936721 T AT 97936721T AT E435281 T1 ATE435281 T1 AT E435281T1
Authority
AT
Austria
Prior art keywords
cadasil
therapeutic use
diagnostic methods
gene related
gene
Prior art date
Application number
AT97936721T
Other languages
English (en)
Inventor
Elisabeth Tournier-Lasserve
Anne Joutel
Marie-Germaine Bousser
Jean-Francois Bach
Original Assignee
Inst Nat Sante Rech Med
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9609733A external-priority patent/FR2751985B1/fr
Application filed by Inst Nat Sante Rech Med, Assist Publ Hopitaux De Paris filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE435281T1 publication Critical patent/ATE435281T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97936721T 1996-08-01 1997-07-31 Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung ATE435281T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9609733A FR2751985B1 (fr) 1996-08-01 1996-08-01 Gene implique dans le cadasil, methode de diagnostic et application therapeutique
FR9704680A FR2751986B1 (fr) 1996-08-01 1997-04-16 Gene implique dans le cadasil, methode de diagnostic et application therapeutique
PCT/FR1997/001433 WO1998005775A1 (fr) 1996-08-01 1997-07-31 Gene implique dans le cadasil, methode de diagnostic et application therapeutique

Publications (1)

Publication Number Publication Date
ATE435281T1 true ATE435281T1 (de) 2009-07-15

Family

ID=26232895

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97936721T ATE435281T1 (de) 1996-08-01 1997-07-31 Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung

Country Status (9)

Country Link
US (3) US6537775B1 (de)
EP (1) EP0915973B1 (de)
JP (2) JP4463329B2 (de)
AT (1) ATE435281T1 (de)
CA (1) CA2262459C (de)
DE (1) DE69739478D1 (de)
ES (1) ES2328304T3 (de)
FR (1) FR2751986B1 (de)
WO (1) WO1998005775A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751986B1 (fr) * 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
US8044259B2 (en) * 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
CA2457879A1 (en) * 2001-08-22 2003-03-06 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
CN1763196B (zh) * 2004-09-13 2010-09-08 首都医科大学宣武医院 基因突变类型及基因测序方法
US7585968B2 (en) * 2005-03-28 2009-09-08 Isis Pharmaceuticals, Inc. Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)
CA2628255C (en) * 2005-10-31 2016-04-19 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2628221A1 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Anti-frizzled receptor antibodies for treating cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
PE20080891A1 (es) * 2006-10-19 2008-08-25 Genentech Inc Anticuerpos anti-notch3 y composiciones que los comprenden
RU2461569C2 (ru) * 2006-10-19 2012-09-20 Дженентек, Инк. Агонистические антитела против notch3 и их применение для лечения notch3-ассоциированных заболеваний
AU2007333805B2 (en) 2006-12-18 2013-07-25 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US20090208491A1 (en) * 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US9127085B2 (en) 2007-08-23 2015-09-08 The Trustees Of Columbia University In The City Of New York Compositions of humanized notch fusion proteins and methods of treatment
US7807630B2 (en) 2007-09-14 2010-10-05 Vanderbilt University Targeting of Notch3 receptor function for cancer therapy
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
WO2010021729A2 (en) * 2008-08-22 2010-02-25 The Trustees Of Columbia University In The City Of New York Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
EP2389390B1 (de) * 2009-01-26 2020-11-04 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Mittel und verfahren zum modulieren der expression des notch3-proteins und/oder der codierenden region von notch3, zusammensetzungen und deren verwendung bei der behandlung von cadasil
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2011140295A2 (en) * 2010-05-06 2011-11-10 President And Fellows Of Harvard College Modulators of notch receptor signaling and methods of use thereof
TW201329105A (zh) 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類ｎｏｔｃｈ１引誘物
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
CA2890571A1 (en) 2012-11-07 2014-05-15 Kenneth G. Geles Anti-notch3 antibodies and antibody-drug conjugates
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US11453718B2 (en) 2017-03-27 2022-09-27 The Schepens Eye Research Institute, Inc. NOTCH3 agonist compositions and methods for treating small vessel diseases
US20230190959A1 (en) * 2017-03-27 2023-06-22 The Schepens Eye Research Institute, Inc. Nucleic acid-based compositions and methods for treating small vessel diseases
US20200103419A1 (en) * 2017-03-27 2020-04-02 The Schepens Eye Research Institute, Inc. Blood biomarkers and diagnostic methods for small vessel diseases
IL307903A (en) * 2021-06-02 2023-12-01 Regeneron Pharma Treatment of cerebrovascular disease with Notts homolog protein factors 3 neurogenic locus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616462A (en) * 1994-02-28 1997-04-01 L'Assistance Publique--Hospitaux de Paris Method for the diagnosis of CADASIL
FR2751986B1 (fr) * 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique

Also Published As

Publication number Publication date
US6537775B1 (en) 2003-03-25
FR2751986B1 (fr) 1998-12-31
US20030186290A1 (en) 2003-10-02
EP0915973A1 (de) 1999-05-19
CA2262459A1 (fr) 1998-02-12
DE69739478D1 (de) 2009-08-13
ES2328304T3 (es) 2009-11-11
WO1998005775A1 (fr) 1998-02-12
CA2262459C (fr) 2013-03-26
JP4463329B2 (ja) 2010-05-19
EP0915973B1 (de) 2009-07-01
JP2001500366A (ja) 2001-01-16
US6995257B1 (en) 2006-02-07
US7138234B2 (en) 2006-11-21
FR2751986A1 (fr) 1998-02-06
JP2010042012A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
ATE435281T1 (de) Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung
DE69841110D1 (de) Verlängerte cdns, die für sekretierte proteine kodieren
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
DE602004011770D1 (de) Fusionsproteine
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DK0910647T3 (da) Human DNase i hyperaktive varianter
DE69824597D1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
EP1194164B8 (de) Prion protein peptide und deren verwendung
TR200700740T2 (tr) Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler
DE3856180D1 (de) Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
ATE455185T1 (de) Atypische protein-kinase-c-isoformen bei erkrankungen des nervensystems und krebs
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
NO20055309D0 (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
DE602004007924D1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
PT782630E (pt) Gene da doenca poliquistica do rim
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE69916829D1 (de) Genetisch veränderte fibroblasten und ihre verwendung
WO2023066873A3 (en) Guide rna and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties